Combined mannitol and deferoxamine therapy for myohemoglobinuric renal injury and oxidant tubular stress. Mechanistic and therapeutic implications.

Mannitol (M) and deferoxamine (DFO) can each protect against myohemoglobinuric acute renal failure (MH-ARF). This study assessed M-DFO interactions during MH-ARF to help discern mechanisms of renal injury, and to define whether M + DFO exerts additive or synergistic antioxidant/cytoprotective effect...

Disgrifiad llawn

Manylion Llyfryddiaeth

Cyhoeddwyd yn:	J Clin Invest
Prif Awdur:	Zager, R A
Fformat:	Artigo
Iaith:	Inglês
Cyhoeddwyd:	American Society for Clinical Investigation 1992
Pynciau:	Research Article
Mynediad Ar-lein:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC329921/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/1325995/ https://ncbi.nlm.nih.govhttps://doi.org/10.1172/JCI115942
Tagiau:	Ychwanegu Tag Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!